Skp2 is oncogenic and overexpressed in human cancers
Compounded semaglutide medications have not been assessed nor approved by Health Canada
This is three times the currently approved 2.4mg dose found in Wegovy
Tirzepatide activates two hormone pathways (GLP-1 and GIP) while retatrutide activates three (GLP-1, GIP, and glucagon)
The evidence consistently demonstrates that semaglutide is generally well-tolerated, with side effects that are predominantly gastrointestinal, mild-to-moderate in severity, transient in duration, and manageable through evidence-based strategies
"There's no standard of care or gold standard on how to wean right now," said Allison Adams, an obesity and internal medicine doctor with UK HealthCare in Kentucky